<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6333">
  <stage>Registered</stage>
  <submitdate>22/08/2016</submitdate>
  <approvaldate>22/08/2016</approvaldate>
  <nctid>NCT02879448</nctid>
  <trial_identification>
    <studytitle>AMPLATZER Amulet LAA Occluder Trial</studytitle>
    <scientifictitle>AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial</scientifictitle>
    <utrn />
    <trialacronym>Amulet IDE</trialacronym>
    <secondaryid>SJM-CIP-10114</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stroke</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Amulet Left Atrial Appendage Occluder
Treatment: devices - WATCHMAN Left Atrial Appendage Closure

Experimental: Amulet - Amulet left atrial appendage occluder

Active Comparator: WATCHMAN (Control) - WATCHMAN left atrial appendage closure device


Treatment: devices: Amulet Left Atrial Appendage Occluder
Transcatheter left atrial appendage closure

Treatment: devices: WATCHMAN Left Atrial Appendage Closure
Transcatheter left atrial appendage closure

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Procedure-related complications, all-cause death, major bleeding - The primary safety endpoint is a composite of procedure-related complications, or all-cause death, or major bleeding through 12 months</outcome>
      <timepoint>12-month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischemic stroke, systemic embolism - The primary efficacy endpoint is a composite of ischemic stroke or systemic embolism through 18 months</outcome>
      <timepoint>18-month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Device closure - The primary mechanism of action endpoint is device closure (defined as residual jet around the device = 5 mm) at the 45-day visit documented by transesophageal echocardiogram (TEE/TOE) defined by Doppler flow</outcome>
      <timepoint>45-days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All stroke, systemic embolism, or cardiovascular/unexplained death - A composite of all stroke, systemic embolism, or cardiovascular/unexplained death at 18 months post-implant</outcome>
      <timepoint>18-month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major bleeding post-device implant - Major bleeding rate at 18 months post-implant: defined as Type 3 or greater based on the Bleeding Academic Research Consortium (BARC) definition</outcome>
      <timepoint>18-month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. 18 years of age or older

          2. Documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)
             and the patient has not been diagnosed with rheumatic mitral valvular heart disease

          3. At high risk of stroke or systemic embolism defined as CHADS2 score &gt; 2 or a
             CHA2DS2-VASc score of &gt; 3

          4. Has an appropriate rationale to seek an alternative to warfarin or other
             anticoagulation medication

          5. Deemed by investigator to be suitable for short term warfarin therapy but deemed
             unable to take long term oral anticoagulation following the conclusion of shared
             decision making (see inclusion criteria #6)

          6. Deemed suitable for LAA closure by a multidisciplinary team of medical professionals
             (including an independent non-interventional physician) involved in the formal and
             shared decision- making process, and by use of an evidence-based decision tool on oral
             anticoagulation (final determination must be documented in the subject's medical
             record)

          7. Able to comply with the required medication regimen post-device implant

          8. Able to understand and willing to provide written informed consent to participate in
             the trial

          9. Able to and willing to return for required follow-up visits and examinations</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Requires long-term oral anticoagulation therapy for a condition other than atrial
             fibrillation

          2. Contraindicated for or allergic to aspirin, clopidogrel, or warfarin use

          3. Indicated for chronic P2Y12 platelet therapy inhibitor

          4. Has undergone atrial septal defect (ASD) repair or has an ASD closure device implanted

          5. Has undergone patent foramen ovale (PFO) repair or has a PFO closure device implanted

          6. Implanted with a mechanical valve prosthesis

          7. Has any of the customary contraindications for a percutaneous catheterization
             procedure (e.g. subject is too small to accommodate the transesophageal echocardiogram
             (TEE/TOE) probe or required catheters, or subject has active infection or bleeding
             disorder)

          8. Stroke or transient ischemic attack (TIA) within 90 days prior to randomization or
             implant procedure (as applicable)

          9. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to
             randomization, or intervention or surgery is planned within 60 days after implant
             procedure

         10. Myocardial infarction (MI) within 90 days prior to randomization

         11. New York Heart Association Class IV Congestive Heart Failure

         12. Left ventricular ejection Fraction (LVEF) &lt;30%

         13. Symptomatic carotid artery disease (defined as &gt;50% stenosis with symptoms of
             ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral
             hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or
             endarterectomy the subject is eligible if there is &lt;50% stenosis

         14. Reversible cause of AF (i.e. secondary thyroid disorders, acute alcohol intoxication,
             trauma, recent major surgical procedures)

         15. History of idiopathic or recurrent venous thromboembolism

         16. Left atrial appendage is obliterated or surgically ligated

         17. Resting heart rate &gt;110 bpm

         18. Thrombocytopenia (defined as &lt; 70,000 platelets/mm3) or anemia with hemoglobin
             concentration of &lt; 10 g/dl (i.e. anemia as determined by the investigator which would
             require transfusion)

         19. Hypersensitivity to any portion of the device material or individual components of
             either the Amulet or Boston Scientific LAA closure device (e.g. nickel allergy)

         20. Actively enrolled or plans to enroll in a concurrent clinical study in which the
             active treatment arm may confound the results of this trial

         21. Subject is pregnant or pregnancy is planned during the course of the investigation

         22. Active endocarditis or other infection producing bacteremia

         23. Subject has a known malignancy or other illness where life expectancy is less than 2
             years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,Wau</recruitmentstate>
    <hospital>Greenslopes Private Hospital - Greenslopes</hospital>
    <hospital>St. Andrew's Hospital - Adelaide</hospital>
    <hospital>HeartCare St John of God Wexford Medical Centre - Murdoch</hospital>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6150 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hesse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rhineland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalusia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castile and Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarre</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Amulet device will be evaluated for safety and efficacy by demonstrating its performance
      is non-inferior to the commercially available WATCHMANÂ® left atrial appendage closure device
      in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial
      will be randomized to receive either the Amulet device or the WATCHMAN device and will be
      followed for 5 years after device implant.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02879448</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dhanunjaya Lakkireddy, MD</name>
      <address>University of Kansas</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Ashish Oza</name>
      <address />
      <phone>818 493 3648</phone>
      <fax />
      <email>aoza@sjm.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>